Molecular identification of basal-like breast cancer through genomic analyses across five cancer types.
Aleix Prat(Hospital Clínic de Barcelona), Javier Cortés(Villa Maria Hospital), Josep Tabernero(Deaconess Hospital), José María Del Campo, Enriqueta Felip(Institut Català d'Ornitologia), Cheng Fan(University of North Carolina at Chapel Hill), María Vidal(Inserm), Patricia Galván(Vall d'Hebron Hospital Universitari), Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 1
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k